RRM1 Monoclonal Antibody

說明書

中文名稱：

RRM1鼠單克隆抗體
貨號：

CSB-MA0205181A0m
規(guī)格：

￥1320
圖片：
Immunohistochemistry of paraffin-embedded human lung cancer using CSB-MA0205181A0m in 30μg/ml dilute concentrations.

Immunohistochemistry of paraffin-embedded human breast cancer using CSB-MA0205181A0m in 30μg/ml dilute concentrations.
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品描述：

RRM1單克隆抗體（CUSABIO貨號：CSB-MA0205181A0m）是針對核糖核苷酸還原酶M1亞基（RRM1）研發(fā)的高特異性科研工具，該靶點作為DNA合成與損傷修復的關(guān)鍵調(diào)控酶，在細胞周期調(diào)控及腫瘤化療耐藥性研究中具有重要價值。本產(chǎn)品采用雜交瘤技術(shù)制備，經(jīng)嚴格的質(zhì)控驗證，適用于人類樣本的ELISA和免疫組化（IHC）檢測，能夠精準識別內(nèi)源性RRM1蛋白的表達定位。在基礎(chǔ)研究領(lǐng)域，該抗體可廣泛應(yīng)用于腫瘤發(fā)生機制探索、化療藥物敏感性研究以及DNA代謝相關(guān)信號通路分析，特別適用于非小細胞肺癌、卵巢癌等實體瘤研究中RRM1蛋白表達水平的定量與定性檢測。其高親和力特性確保在復雜樣本基質(zhì)中仍能保持優(yōu)異的檢測靈敏度，為揭示RRM1在腫瘤微環(huán)境調(diào)控、基因組穩(wěn)定性維持等前沿課題提供可靠技術(shù)支撐。通過優(yōu)化抗原表位選擇及純化工藝，本產(chǎn)品在組織切片染色和蛋白免疫分析中展現(xiàn)出高度一致性，是癌癥分子生物學研究和轉(zhuǎn)化醫(yī)學實驗的理想選擇。
產(chǎn)品名稱：

mouse anti-Homo sapiens (Human) RRM1 monoclonal antibody
Uniprot No.：

P23921
基因名：

RRM1
別名：

R1 antibody; Ribonucleoside diphosphate reductase large subunit antibody; Ribonucleoside diphosphate reductase M1 chain antibody; Ribonucleoside diphosphate reductase subunit M1 antibody; Ribonucleoside reductase; large subunit antibody; Ribonucleoside-diphosphate reductase large subunit antibody; Ribonucleoside-diphosphate reductase subunit M1 antibody; Ribonucleotide reductase large chain antibody; Ribonucleotide reductase large subunit antibody; Ribonucleotide reductase M1 antibody; Ribonucleotide reductase M1 polypeptide antibody; Ribonucleotide reductase R1 subunit antibody; Ribonucleotide reductase; M1 subunit antibody; RIR 1 antibody; RIR1 antibody; RIR1_HUMAN antibody; RR 1 antibody; RR1 antibody; RRM 1 antibody; RRM1 antibody
宿主：

mouse
反應(yīng)種屬：

Human
免疫原：

Recombinant Human RRM1 Protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

monoclonal
純化方式：

>95%,protein G purifed
克隆號：

3D6H5
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

liquid
應(yīng)用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:500

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.
基因功能參考文獻：
1. The evaluation of RRM1 gene expression in cfRNA allows for estimation of the risk of severe oral mucositis (OM) in patients subjected to radiotherapy PMID: 29865035
2. The expression of RRM1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. PMID: 29214667
3. Our results therefore demonstrate that RRM1 is a novel therapeutic target in multiple myeloma in the preclinical setting and provide the basis for clinical evaluation of RRM1 inhibitor, alone or in combination with DNA-damaging agents, to improve patient outcome in multiple myeloma PMID: 28442502
4. three SNPs (corepressor interacting with RBPJ 1 (CIR1) rs13009079T>C, ribonucleotide reductase M1 (RRM1) rs1465952T>C and solute carrier family 38, member 4 (SLC38A4) rs2429467C>T), may play a role in the pathogenesis of lung cancer PMID: 27587543
5. TP53 mutant cancer cells had elevation of ribonucleotide reductase subunit 1 (RRM1) and 2 (RRM2), which was reduced by inhibition of mTORC1. PMID: 28507282
6. The genetic polymorphisms RRM1 -756T>C and -269C>A may not be a factor for susceptibility to cervical neoplasia PMID: 27179014
7. Based on the results of clinical trials, we conclude that Ribonucleotide reductase (RR) enzymes (RR1 and RR2)inhibitors are viable treatment options, either as a monotherapy or as a combination in cancer chemotherapy. With the recent advances made in cancer biology, further development of RR inhibitors with improved efficacy and reduced toxicity is possible for treatment of variety of cancers. PMID: 28624910
8. RRM1 single nucleotide polymorphism is associated with Non-Small-Cell Lung Cancer. PMID: 27908619
9. RRM1/RRM2B enzyme is capable of retaining activity in hypoxia and therefore is favored over RRM1/RRM2 in order to preserve ongoing replication and avoid the accumulation of DNA damage in hypoxic cells. PMID: 28416140
10. findings suggest that the up-regulated RRM1 and hTrx1 in colorectal cancer directly interact with each other and promote RR activity, resulting in enhanced DNA synthesis and cancer malignancy. PMID: 28411237
11. RRM1 and ERCC1 expression levels did not show any relationship with overall survival. PMID: 26612755
12. RRM1 and ERCC wild type alleles are risk-reducing factor for Coronary artery disease (CAD). Also, carrying RRM1 A allele might have a protective effect for smokers. PMID: 27566080
13. Presence of rare AA (-37C>A) and CC (-524C>T) genotypes of the RRM1 may be favorable predictive factors for chemotherapy with platinum compounds and gemcitabine in non-small cell lung cancer patients. PMID: 26650486
14. study finds that ERCC1 and RRM1 are not independent prognostic factors of recurrence in stage I non-small cell lung cancer patients PMID: 26542178
15. mRNA expression of RRM1 was closely associated with cell proliferation and varied in seven non-Hodgkin lymphoma cell lines. PMID: 27173327
16. A significant association has been found between RRM1 rs12806698 (-269C>A) RRM1 genotype and the risk for developing non-small cell lung cancer. PMID: 26718430
17. Results underline the relevance of microRNA-101-3p-driven regulation of RRM1 in pancreatic ductal carcinoma gemcitabine resistance. PMID: 26828016
18. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer PMID: 26323924
19. TUBB3, TOP2A, CYP19A1 and CYP2D6 gene expression, but not protein expression, was associated with patient survival. PMID: 26252353
20. A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. PMID: 26637889
21. RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy PMID: 26200905
22. RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1) and ribonucleotide reductase M1 (RRM1) were significantly higher and cytidine deaminase (CDA) was significantly lower in ex vivo Ara-C sensitive samples. PMID: 26083014
23. It is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells. PMID: 25837929
24. For RRM1 C37A-T524C genotype, sensitive group had higher proportion of high effective genotype than non-sensitive group (p=0.009). PMID: 26028097
25. Adenoviral vector expressing short hairpin RNA targeting RRM1 exerts potent antitumor effects and increases sensitivity to gemcitabine. PMID: 26254808
26. Data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance. PMID: 25497672
27. These in vitro results suggest that mRNA expression levels of the RRM1 and ABCB1 genes may be useful indicators of chemosensitivity to gemcitabine and cisplatin. PMID: 25560468
28. The oligomerization-directed fluorescence quenching of hRNR-alpha, covalently labeled with two fluorophores, allows for direct readout of hRNR dimeric and hexameric states. PMID: 25256246
29. RRM1 expression was identified as independent prognosticators for freedom from recurrence of malignant pleural mesothelioma in patients undergoing induction chemotherapy followed by extrapleural pneumonectomy. PMID: 25840756
30. In Turkish population RRM1 rs12806698 carriers have nearly twofold risk for development of head and neck squamous epithelial cell cancer. PMID: 24861915
31. Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression. PMID: 25078585
32. Gene polymorphisms of RRM1 -756T>C and RRM1 -269C>A may be not an important factor for the susceptibility of breast cancer. PMID: 24578158
33. concomitant low expression levels of ERCC1, RRM1, and RRM2 and the high expression level of BRCA1 were predictive of a better outcome. PMID: 25227663
34. RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival in nonsmall cell lung cancer patients treated with gemcitabine plus cisplatin. PMID: 24591771
35. RRM1 IHC expression tailored selection of first-line therapy could improve therapeutic outcomes in patients with advanced NSCLC. PMID: 24595080
36. High intratumoural hENT1 and low RRM1 expression were independently associated with prolonged disease-free survival in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. PMID: 25032731
37. High RRM1 expression is associated with non-small cell lung cancer. PMID: 23803067
38. No change in RRM1 expression was observed in primary NSCLC tumours, but expression seemed to be higher in N2 lymph node metastases following chemotherapy. PMID: 24266856
39. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PMID: 23922955
40. we found no support of the hypothesis that aberrations of RRM1 or RRM2B, neither individually nor in combination, are associated with an altered clinical outcome following chemotherapy. PMID: 24215511
41. We observed an increase of ORR in NSCLC patients when they were treated with chemotherapy according to ERCC1 and RRM1 SNPs status. PMID: 24045016
42. low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in non-small cell lung cancer PMID: 24155212
43. RRM1 preserves chromosomal stability via the CHK1- and CDK1-dependent stabilization of the centrosomal integrity at the replication stage. PMID: 24434653
44. Genetic polymorphisms in SLC28A3, SLC29A1 and RRM1 can influence the clinical outcome of metastatic breast cancer patients treated with paclitaxel-gemcitabine chemotherapy. PMID: 24361227
45. The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine PMID: 23982437
46. These results suggest that SNPs within ribonucleotide reductase (RRM1 and RRM2) might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts. PMID: 24024897
47. Low RRM1 expression is associated with response to therapy in pancreatic cancer. PMID: 23991987
48. RR1 expression may discriminate cervical cancer phenotype and radiochemotherapy outcome PMID: 23552804
49. The expressions of MDR-1, RRM-1, EGFR, ERCC-1 were observed in a variety of pathological types of NSCLC. PMID: 23948418
50. Report essential roles for ribonucleotide reductase and thymidylate synthase in C-MYC-dependent suppression of senescence in melanoma cells. PMID: 23249808
顯示更多

收起更多
亞細胞定位：

Cytoplasm.
蛋白家族：

Ribonucleoside diphosphate reductase large chain family
數(shù)據(jù)庫鏈接：

HGNC: 10451

OMIM: 180410

KEGG: hsa:6240

STRING: 9606.ENSP00000300738

UniGene: Hs.445705

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human